Hypertrophic Cardiomyopathy

  • Tyler J. SlyngstadEmail author
  • Christopher J. Cove


Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease process that leads to variable clinical presentations and outcomes. Many individuals with HCM will remain asymptomatic or only mildly symptomatic throughout life and require no medical intervention. Identification and treatment of symptomatic and high-risk patients and their families remains the cornerstone of management. Indicated treatment is aimed at three interrelated processes of heart failure, sudden cardiac death, and atrial fibrillation.


Genetic Cardiomyopathy Hypertrophy Sudden cardiac death Syncope Heart failure Dynamic outflow tract obstruction Septal anterior motion 


  1. 1.
    Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705–15.CrossRefGoogle Scholar
  3. 3.
    Maron MS, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol. 2010;105(12):1842–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Maron MS, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Sherrid MV, et al. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22(3):816–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Carasso S, et al. Diastolic myocardial mechanics in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2010;23(2):164–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Maron MS, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(9):866–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Biagini E, et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(12):1727–31.CrossRefPubMedGoogle Scholar
  10. 10.
    McLeod CJ, et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol. 2009;54(3):229–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Gersh BJ, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(25):2703–38.CrossRefPubMedGoogle Scholar
  12. 12.
    Adabag AS, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51(14):1369–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Maron MS, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Ommen SR, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Nagueh SF, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol. 2011;58(22):2322–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Agarwal S, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55(8):823–34.CrossRefPubMedGoogle Scholar
  17. 17.
    Olivotto I, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Rochester Medical Center/CardiologyRochesterUSA

Personalised recommendations